Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®)

Gian Maria Busetto, Riccardo Giovannone, Matteo Ferro, Stefano Tricarico, Francesco Del Giudice, Deliu Victor Matei, Ottavio De Cobelli, Vincenzo Gentile, Ettore De Berardinis, Gian Maria Busetto, Riccardo Giovannone, Matteo Ferro, Stefano Tricarico, Francesco Del Giudice, Deliu Victor Matei, Ottavio De Cobelli, Vincenzo Gentile, Ettore De Berardinis

Abstract

Background: Bacterial prostatitis (BP) is a common condition accounting responsible for about 5-10% of all prostatitis cases; chronic bacterial prostatitis (CBP) classified as type II, are less common but is a condition that significantly hampers the quality of life, (QoL) because not only is it a physical condition but also a psychological distress. Commonly patients are treated with antibiotics alone, and in particular fluoroquinolones are suggested by the European Urology guidelines. This approach, although recommended, may not be enough. Thus, a multimodal approach to the prolonged antibiotic therapy may be helpful.

Methods: 210 patients affected by chronic bacterial prostatitis were enrolled in the study. All patients were positive to Meares-Stamey test and symptoms duration was > 3 months. The purpose of the study was to evaluate the efficacy of a long lasting therapy with a fluoroquinolone in association with a nutraceutical supplement (prulifloxacin 600 mg for 21 days and an association of Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg for 30 days). Patients were randomized in two groups (A and B) receiving respectively antibiotic alone and an association of antibiotic plus supplement.

Results: Biological recurrence at 2 months in Group A was observed in 21 patients (27.6%) and in Group B in 6 patients (7.8%). Uropathogens found at the first follow-up were for the majority Gram - (E. coli and Enterobacter spp.). A statistically significant difference was found at the time of the follow-up between Group A and B in the NIH-CPSI questionnaire score, symptoms evidence and serum PSA.

Conclusions: Broad band, short-lasting antibiotic therapy in association with a nutritional supplement (serenoa repens, lactobacillus sporogens and arbutin) show better control and recurrence rate on patients affected by chronic bacterial prostatitits in comparison with antibiotic treatment alone.

Trial registration: NCT02130713. Date of trial Registration: 30/04/2014.

Figures

Figure 1
Figure 1
NIH-CPSI questionnaire. NIH-CPSI questionnaire score at baseline, 2nd, 4th and 6th month.
Figure 2
Figure 2
PSA. Serum PSA at baseline, 2nd, 4th and 6th month.
Figure 3
Figure 3
Symptoms. Presence of symptoms at baseline, 2nd, 4th and 6th month.

References

    1. Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome. Urol Clin North Am. 2008;35:81–89. doi: 10.1016/j.ucl.2007.09.005.
    1. Wenninger K, Heiman JR, Rothman I, Berghuis JP, Berger RE. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol. 1996;155:965–968. doi: 10.1016/S0022-5347(01)66359-6.
    1. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 2008;179:S61–S67. doi: 10.1016/j.juro.2008.03.139.
    1. Mazzoli S. Conventional bacteriology in prostatitis patients: microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch Ital Urol Androl. 2007;79:71–75.
    1. Nickel JC, Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J Urol. 2008;179:1391–1395. doi: 10.1016/j.juro.2007.11.081.
    1. Bjerklund Johansen TE, Grüneberg RN, Guibert J, Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, Palou Redorta J, van Cangh PJ. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 1998;34(6):457–466. doi: 10.1159/000019784.
    1. Naber KG. Antimicrobial treatment of bacterial prostatitis. Eur Urol. 2003;43(Suppl 2):23–26.
    1. Stamey TA, Meares EM, Winningham DG. Chronic bacterial prostatitis and diffusion of drugs into prostatic fluid. J Urol. 1970;103:187–194.
    1. Shoskes DA. Phytotherapy in chronic prostatitis. Urology. 2002;60(Suppl 6A):35–37.
    1. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol. 2004;171:284–288. doi: 10.1097/01.ju.0000101487.83730.80.
    1. Lee HJ, KIM KW. Anti-inflammatory effects of arbutin in lypopolysaccharide-stimulated BV2 microglial cells. Inflamm Res. 2012;61(8):817–825. doi: 10.1007/s00011-012-0474-2.
    1. Liu L, Yang J, Lu F. Urethral dysbacteriosis as an underlying, primary cause of chronic prostatitis: potential implications for probiotic therapy. Med Hypotheses. 2009;73:741–743. doi: 10.1016/j.mehy.2009.04.035.
    1. Amdekar S, Singh V, Singh DD. Probiotic therapy: immunomodulating approach toward urinary tract infection. Curr Microbiol. 2011;63(5):484–490. doi: 10.1007/s00284-011-0006-2.
    1. Probert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, Nyberg LM, Schaeffer AJ. Chronic Prostatitis Collaborative Research Network. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2002;59(6):870–876. doi: 10.1016/S0090-4295(02)01601-1.
    1. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, Barbone F, Selli C. Prulifloxacin versul levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother. 2007;19(3):304–308. doi: 10.1179/joc.2007.19.3.304.
    1. Magri V, Trinchieri A, Pozzi G, Restelli A, Garlaschi MC, Torresani E, Zirpoli P, Marras E, Perletti G. Efficacy of repeated cyclesnof combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob Agents. 2007;29:549–556. doi: 10.1016/j.ijantimicag.2006.09.027.
    1. Cai T, Mazzoli S, Bechi A, Addonisio P, Mondaini N, Pagliai RC, Bartoletti R. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents. 2009;33(6):549–553. doi: 10.1016/j.ijantimicag.2008.11.012.
    1. Schaeffer AJ, Weidner W, Barbalias GA. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2003;3(Suppl 2):1–4.
    1. Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2012;110(7):1014–1022. doi: 10.1111/j.1464-410X.2012.11088.x.
    1. Shoskes DA. Phytotherapy and other alternative forms of care for the patients with prostatitis. Curr Urol Rep. 2002;3:330. doi: 10.1007/s11934-002-0059-7.
    1. Giberti C, Gallo F, Rosignoli MT, Ruggieri A, Barattè S, Picollo R, Dionisio P. Penetration of orally administered prulifloxacin into human prostate tissue. Clin Drug Investig. 2009;29(1):27–34. doi: 10.2165/0044011-200929010-00003.
    1. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280(18):1604–1609. doi: 10.1001/jama.280.18.1604.
    1. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D’Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998;37(2):77–83. doi: 10.1002/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>;2-I.
    1. Weinstock LB, Geng B, Brandes SB. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin. Can J Urol. 2011;18(4):5826–5830.
    1. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol. 1982;54:729–731. doi: 10.1111/j.1464-410X.1982.tb13635.x.
    1. Fraga M, Scavone P, Zunino P. Preventive and therapeutic administration of an indigenous Lactobacillus sp. Strain against Proteus mirabilis ascending urinary tract infection in a mouse model. Antoine Ven Leeuwenhoek. 2005;88:25–34. doi: 10.1007/s10482-004-5475-x.
    1. Shoskes DA, Hakim L, Ghoniem G, Jackson CL. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2003;169(4):1406–1410. doi: 10.1097/01.ju.0000055549.95490.3c.
    1. Bruyere F, Amine LM. PSA interest and prostatitis: literature review. Prog Urol. 2013;23(16):1377–1381. doi: 10.1016/j.purol.2013.05.009.
    1. Magri V, Trinchieri A, Ceriani I, Marras E, Perletti G. Eradication of unusual pathogens by combination pharmacological tharapy is parallel by improvement of signs and symptoms of chronic prostatitis syndrome. Arch Ital Urol Androl. 2007;79:93–98.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅